Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
Status:
Completed
Trial end date:
2016-12-08
Target enrollment:
Participant gender:
Summary
This is a multicenter, non-randomized, single-dose, open-label study conducted in male and
surgically sterile or post-menopausal female participants with stable chronic hepatic
impairment and in healthy participants matched by age, gender, and body weight to assess the
effect of hepatic impairment on the pharmacokinetics of alectinib.